U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for priority review with a PDUFA date of July 22, 2025 ...
Over the next few years, we expect Sensata to prioritize cash flow generation and organic investment. As of Dec. 31, 2024, the firm carried $3.2 billion in total debt and $594 million in cash and ...
Prevas is reporting the highest sales figures in its history for both the full year and the last quarter of the year. We are now summing up 2024, a year in which our long-term business model and opera ...
Aptar has a narrow economic moat, with durable switching costs in the Pharma business supported by intangible assets throughout the product portfolio from expertise in product regulation, design, and ...